ClinicalTrials.gg
CompletedNCT04673617Updated Apr 3, 2026

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

A Phase 1/2 interventional study of AB-101 and Rituximab in Non Hodgkin Lymphoma, sponsored by Artiva Biotherapeutics, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Artiva Biotherapeutics, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States — 140 open to participants now, 255 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Enrollment
568th of 1,377
45 · median 35
Started
2021
with 53 others
Phase 1/2
205 of 1,599
22 open now
Registered
1,374th of 1,599
by date

Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 568th largest by enrollment of the 1,377 interventional ones that give a count, is one of 54 that started in 2021, is one of 205 in phase 1/2, and was the 1,374th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

140 of the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

135 more — sign in →

All 140 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells.

This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients.

Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.

03

Conditions studied

  • Non Hodgkin Lymphoma

Keywords

  • lymphoma
  • NHL
  • cell therapy
  • rituximab
  • NK cell
  • bendamustine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of aggressive NHL of B-cell origin. For enrollment into the DLBCL specific cohort: DLBCL, High-grade B-cell Lymphoma or PMBCL.
  • Patient must have progressed or demonstrated intolerance to at least two lines of FDA-approved therapies, one of which must have included anti-CD20 monoclonal antibody therapy. The following are permitted: Prior hematopoietic stem cell transplantation, prior treatment with FDA-approved CAR-T therapy, and/or prior treatment with an agent. Prior treatment(s) with an FDA-approved CAR-T cell therapy or other cell therapies is permitted as long the patients are not considered to be to this previous cell therapy approach (defined as progression within 120 days from the infusion of the cell therapy approach).
  • Patient must have disease that allows for response assessment using the Lugano classification criteria.
  • Ability to understand and sign the ICF.

Exclusion criteria

Exclusion Criteria:

  • Active CNS lymphoma or CNS involvement unless there is a history of at least 3 months of sustained remission of treated disease.
  • History of structural cardiac disease.
  • Cardiac of \< 45% on echocardiogram or MUGA scan at screening assessment.
  • Inadequate pulmonary function.
  • History of a solid organ allograft, or an inflammatory or disease likely to be exacerbated by IL-2.
  • Ongoing uncontrolled systemic infections.
  • Positive PCR test
  • Positive for or
  • Prior stem cell transplant.
  • Females of must be willing and able to use appropriate for duration of trial and for 6 months following final AB-101 dose. Males must be sterile or commit to using appropriate contraception until 90 days following the final dose of AB-101.
  • Individuals who are pregnant or lactating are ineligible.
  • Patients who received a previous genetically modified cell therapy product (e.g., CD19 CAR-T), and progressed within 120 days from the time of the cell therapy infusion
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Phase 1: Dose confirmation of AB-101 as mono, ritux combo (including DLBCL specific) & BR combo

    Phase 1: Dose confirmation of AB-101 as monotherapy, in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab

    Drug: AB-101 · Drug: Rituximab · Drug: Interleukin-2 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

  • Experimental
    Phase 2: AB-101 given with rituximab or with BR to patients with B-cell NHL at the R2PD

    Phase 2: AB-101 given with rituximab or with bendamustine and rituximab to patients with B-cell NHL at the R2PD

    Drug: AB-101 · Drug: Rituximab · Drug: Interleukin-2 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1: Safety and tolerability of AB-101 as monotherapy, and in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab.

    Based on incidence, severity, and dose relationship of AEs and serious AEs (SAEs)

    Time frame: From the ICF signature through 13 weeks after last study drug dose.

  2. Phase 1, combination therapy: AB-101 clinical activity, determined by ORR

    Objective response rate (ORR) is defined as the proportion of patients with a documented complete response or partial response (CR + PR) in the absence of earlier disease progression.

    Time frame: From baseline disease assessment through end of study participation.

  3. Phase 1, combination therapy: Identify the recommended Phase 2 dose (R2PD) for AB-101.

    R2PD will be determined based on safety and tolerability of AB-101 in combination with rituximab or in combination with bendamustine and rituximab.

    Time frame: From ICF signature through 13 weeks after last study drug dose.

  4. Phase 2: Determine the efficacy profile of AB-101 in combination with rituximab or in combination with bendamustine and rituximab when administered to patients with R/R NHL of B-cell origin.

    The efficacy profile will be determined by the ORR.

    Time frame: From baseline disease assessment through end of study participation.

07

Study locations

21 sites
  • Artiva Clinical Trial Site
    Birmingham, Alabama 35249, United States
  • Artiva Clinical Trial Site
    Tucson, Arizona 85719, United States
  • Artiva Clinical Trial Site
    Orange, California 92868, United States
  • Artiva Clinical Trial Site
    San Diego, California 92093, United States
  • Artiva Clinical Trial Site
    Gainesville, Florida 32608, United States
  • Artiva Clinical Trial Site
    Atlanta, Georgia 30342, United States
  • Artiva Clinical Trial Site
    Chicago, Illinois 60612, United States
  • Artiva Clinical Trial Site
    Iowa City, Iowa 52242, United States
  • Artiva Clinical Trial Site
    Wichita, Kansas 67214, United States
  • Artiva Clinical Trial Site
    Louisville, Kentucky 40241, United States
  • Artiva Clinical Trial Site
    Detroit, Michigan 48201, United States
  • Artiva Clinical Trial Site
    Lake Success, New York 11042, United States
  • Artiva Clinical Trial Site
    New York, New York 11021, United States
  • Artiva Clinical Trial Site
    Columbus, Ohio 43214, United States
  • Artiva Clinical Trial Site
    Portland, Oregon 97239, United States
  • Artiva Clinical Trial Site
    Philadelphia, Pennsylvania 19107, United States
  • Artiva Clinical Trial Site
    Philadelphia, Pennsylvania 19111, United States
  • Artiva Clinical Trial Site
    Providence, Rhode Island 02903, United States
  • Artiva Clinical Trial Site
    Dallas, Texas 75246, United States
  • Artiva Clinical Trial Site
    Salt Lake City, Utah 84112, United States
  • Artiva Clinical Trial Site
    Richmond, Virginia 23298, United States
08

References and documents

Individual participant data

Plan to share: No — AlloNK is early in clinical development, next steps will be based on the progress of our data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Oct 2025, 54 months.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's 54 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2020
First posted
Dec 17, 2020
StartActual
Mar 29, 2021
Primary completionActual
Oct 6, 2025
CompletionActual
Oct 6, 2025
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04673617
Lead sponsor
Artiva Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 17, 2020
Start date
Mar 29, 2021
Primary completion
Oct 6, 2025
Completion
Oct 6, 2025
Last update
Apr 3, 2026

Study contacts

Subhashis Banerjee, M.D.
study director · Artiva Biotherapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AB-101

Start the discussion